Report of Foreign Issuer (6-k)
May 07 2018 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 4, 2018
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk
A/S purchases B shares worth DKK 1,038 million from Novo Holdings A/S under the 2018 share repurchase programme
Bagsværd, Denmark, 4 May 2018
- Novo Nordisk A/S has today entered into an agreement
to purchase 3,415,895 B shares (nominal DKK 0.20) of a value of DKK 1,038 million from Novo Holdings A/S. This transaction is
part of Novo Nordisk's 2018 share repurchase programme of up to a total of DKK 14.0 billion to be executed during a 12 months
period beginning 1 February 2018. The transaction price is DKK 303.83 per share and has been calculated as the volume weighted
average market price from 2 May to 4 May 2018 in the open window following the announcement of Novo Nordisk A/S' quarterly financial
results.
Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk
A/S was 28.5% of the share capital and 76.2% of the votes. Following the transaction, Novo Holdings A/S
owns 537,436,000 A shares of DKK 0.20 and 157,310,695 B shares of DKK 0.20, corresponding to 28.4% of the
capital and 76.2% of the votes in Novo Nordisk A/S.
The
transaction is in line with the announcement on 2 May 2018 that Novo Holdings A/S intends
to maintain its ownership of Novo Nordisk A/S' share capital around 28%.
Transactions
related to Novo Nordisk A/S' incentive programmes have resulted in a net transfer from
Novo Nordisk of 3,155 B shares of DKK 0.20 in the period from 2 May 2018 to 4 May 2018.
Novo Nordisk A/S owns a total of 24,743,093 B shares of DKK 0.20, corresponding to 1.0%
of the share capital, as treasury shares including this transaction. The total amount
of A and B shares in the company is 2,450,000,000 of DKK 0.20 including treasury shares.
Page
2 of 2
About Novo Holdings A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding
company of the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation's
assets.
In addition to being the major
shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes
significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.
It is the vision of Novo Holdings
to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novo-holdings.dk.
About Novo Nordisk A/S
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets
its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Novo
Holdings Communication
|
|
|
Christian
Mostrup Scheel
|
+45
3067 4805
|
cims@novo.dk
|
|
|
|
Novo
Nordisk Media:
|
|
|
Katrine
Sperling
|
+45
3079 6718
|
krsp@novonordisk.com
|
Ken
Inchausti (US)
|
+1
609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Novo
Nordisk Investors
:
|
|
|
Peter
Hugreffe Ankersen
|
+45
3075 9085
|
phak@novonordisk.com
|
Anders
Mikkelsen
|
+45
3079 4461
|
armk@novonordisk.com
|
Christina
Kjær
|
+45
3079 3009
|
cnje@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 39 / 2018
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 4, 2018
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024